116.10
+1.48%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Insmed
From its filings with the US Securities and Exchange Commission
Insmed is based in Bridgewater, New Jersey and is incorporated in Virginia. Its shares trade on Nasdaq under the ticker INSM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $606.4m and a net loss of $1.28bn. At that date it held total assets of $2.26bn and shareholders' equity of $739.0m. By business, ARIKAYCE brought in 71.5% of revenue, followed by BRINSUPRI at 28.5%. By region, US accounted for 74.7%, followed by International at 25.3%.
We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates and technologies.
BRINSUPRI (brensocatib 25 mg and 10 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (referred to as bronchiectasis or NCFB) in patients 12 years of age and older, was approved in the US in August 2025. In November 2025, the EC approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months. Bronchiectasis is a serious, chronic lung disease in which the bronchi become permanently dilated due to a cycle of infection, inflammation, and lung tissue damage.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Feb 1991
- Employees
- 1,664
- Website
- insmed.com ↗
- Head office
- 700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807
- Incorporated in
- VA
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. William LewisChairman of the Board, Chief Executive Officer, since 2012$10.9m
- Ms. Sara BonsteinChief Financial Officer$4.0m
- Mr. Roger AdsettChief Operating Officer$4.3m
- Ms. S. Nicole SchaefferChief People Strategy Officer$2.7m
- Dr. Martina FlammerChief Medical Officer$4.1m
- Mr. Michael SmithChief Legal Officer
- Mr. David BrennanLead Independent Director$435,000
- Ms. Elizabeth AndersonIndependent Director$400,000
- Dr. Clarissa DesjardinsIndependent Director$405,000
- Mr. Leo LeeIndependent Director$407,500
- Mr. David McgirrIndependent Director$410,000
- Ms. Carol SchaferIndependent Director$405,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 75
- Environment
- 82
- Social
- 99
- Governance
- 45
- Direct emissions (scope 1)
- 1,109 t
- Energy emissions (scope 2)
- 1,122 t
- Women in the workforce
- 53%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Insmed Inc has several strengths that contribute to its success. One major strength is its innovative product portfolio, which includes unique and effective treatments. The company's strong research and development capabilities allow it to continuously develop new products and stay ahead of the competition. Additionally, Insmed Inc has a strong financial position and a solid track record of revenue growth.
Weaknesses
- Despite its strengths, Insmed Inc also faces some weaknesses that need to be addressed. One major weakness is its heavy reliance on key suppliers for raw materials and components. Any disruption in the supply chain can significantly impact the company's operations. Moreover, the company has limited geographical diversification, relying heavily on a few key markets for its revenue.
Opportunities
- Insmed Inc has various opportunities to capitalize on. The increasing prevalence of chronic diseases presents a growing market for the company's products. By expanding its product portfolio and penetrating new geographic markets, Insmed Inc can further fuel its growth. Additionally, advancements in technology and the rise of digital healthcare open doors for the company to explore innovative solutions and enhance its market presence.
Threats
- Insmed Inc faces certain threats that may impact its business. One significant threat is the intense competition within the pharmaceutical industry. The presence of well-established competitors with similar offerings poses a challenge to Insmed Inc's market share. Additionally, regulatory changes and stringent approval processes for new drugs can hinder the company's ability to bring products to market quickly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.